PIK3CA-related overgrowth

Clinical trials for PIK3CA-related overgrowth explained in plain language.

Never miss a new study

Get alerted when new PIK3CA-related overgrowth trials appear

Sign up with your email to follow new studies for PIK3CA-related overgrowth, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Terminated 1

Could a cancer drug tame rare overgrowth disease?

Disease control Stopped early

This early-phase trial tested taselisib, a drug that blocks a faulty protein causing excessive growth in people with PIK3CA-related overgrowth. Nineteen participants took the drug daily for four weeks to see if it was safe and tolerable. The study was stopped early, so we have li…

Matched conditions: PIK3CA-RELATED OVERGROWTH

Phase 1/2 • Sponsor: Centre Hospitalier Universitaire Dijon • Aim: Disease control

Last updated Jun 27, 2026 09:01 UTC

PIK3CA-related overgrowth

Get alerted when new PIK3CA-related overgrowth trials appear

Could a cancer drug tame rare overgrowth disease?